HK1205789A1 - Method for selecting or identifying a subject for v1b antagonist therapy v1b - Google Patents

Method for selecting or identifying a subject for v1b antagonist therapy v1b

Info

Publication number
HK1205789A1
HK1205789A1 HK15106312.1A HK15106312A HK1205789A1 HK 1205789 A1 HK1205789 A1 HK 1205789A1 HK 15106312 A HK15106312 A HK 15106312A HK 1205789 A1 HK1205789 A1 HK 1205789A1
Authority
HK
Hong Kong
Prior art keywords
identifying
selecting
subject
antagonist therapy
antagonist
Prior art date
Application number
HK15106312.1A
Other languages
English (en)
Chinese (zh)
Inventor
David A Katz
Marcel Van Gaalen
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1205789A1 publication Critical patent/HK1205789A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK15106312.1A 2012-03-13 2015-07-02 Method for selecting or identifying a subject for v1b antagonist therapy v1b HK1205789A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610101P 2012-03-13 2012-03-13
PCT/EP2013/055147 WO2013135769A1 (en) 2012-03-13 2013-03-13 Method for selecting or identifying a subject for v1b antagonist therapy

Publications (1)

Publication Number Publication Date
HK1205789A1 true HK1205789A1 (en) 2015-12-24

Family

ID=47846064

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106312.1A HK1205789A1 (en) 2012-03-13 2015-07-02 Method for selecting or identifying a subject for v1b antagonist therapy v1b

Country Status (14)

Country Link
US (1) US20130245038A1 (xx)
EP (1) EP2825891A1 (xx)
JP (1) JP2015512892A (xx)
KR (1) KR20140147837A (xx)
CN (1) CN104303060A (xx)
AU (1) AU2013231230A1 (xx)
BR (1) BR112014018717A8 (xx)
CA (1) CA2866220A1 (xx)
HK (1) HK1205789A1 (xx)
MX (1) MX2014011045A (xx)
RU (1) RU2014141059A (xx)
SG (1) SG11201405214YA (xx)
WO (1) WO2013135769A1 (xx)
ZA (1) ZA201406518B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
CN109030828A (zh) * 2018-06-21 2018-12-18 大连民族大学 一种检测组氨酸磷酸化蛋白的elisa检测试剂盒及检测方法
CN108845145A (zh) * 2018-06-21 2018-11-20 大连民族大学 一种检测组氨酸激酶活性的方法
MX2021005801A (es) * 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
CN114624344A (zh) * 2020-12-10 2022-06-14 中国科学院大连化学物理研究所 一种类固醇激素联合生物标志物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1362776A (en) * 1970-07-17 1974-08-07 Wellcome Found Immunological reagent
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
ATE111083T1 (de) 1986-10-22 1994-09-15 Abbott Lab Chemilumineszierende acridinium- und phenantridiniumsalze.
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
ES2198823T3 (es) 1992-03-30 2004-02-01 Abbott Laboratories Reactivos que permiten la deteccion y la cuantificacion de la tiroxina en muestras de fluido.
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
MXPA03000506A (es) 2000-07-18 2004-09-10 Correlogic Systems Inc Proceso para discriminiar entre estados biologicos basados en patrones escondidos de datos biologicos.
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
CA2484625A1 (en) 2002-05-09 2003-11-20 Surromed, Inc. Methods for time-alignment of liquid chromatography-mass spectrometry data
US7309468B2 (en) * 2002-05-13 2007-12-18 Becton, Dickinson And Company Protease inhibitor sample collection system
WO2008137270A1 (en) * 2007-05-04 2008-11-13 H. Lundbeck A/S Methods of diagnosing and monitoring of npy y5 based disorders
CN102016907A (zh) * 2008-03-12 2011-04-13 瑞吉诊断公司 用于监测抑郁症的炎性生物标志物
WO2009130232A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
CA2767458A1 (en) * 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods

Also Published As

Publication number Publication date
SG11201405214YA (en) 2014-10-30
BR112014018717A2 (xx) 2017-06-20
US20130245038A1 (en) 2013-09-19
AU2013231230A1 (en) 2014-08-07
RU2014141059A (ru) 2016-04-27
EP2825891A1 (en) 2015-01-21
KR20140147837A (ko) 2014-12-30
CN104303060A (zh) 2015-01-21
MX2014011045A (es) 2015-04-10
BR112014018717A8 (pt) 2017-07-11
CA2866220A1 (en) 2013-09-19
AU2013231230A8 (en) 2014-08-14
ZA201406518B (en) 2018-05-30
JP2015512892A (ja) 2015-04-30
WO2013135769A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
IL234875B (en) A method for detecting a copy number change
EP2847353A4 (en) METHOD FOR DETERMINING A NUCLEOTIDE SEQUENCE
ZA201501833B (en) Method for obtaining 1-kestone
EP2897709A4 (en) METHOD FOR SEPARATING CELLULAR BUG COMPLEXES
HK1208534A1 (en) A method for authenticating a timepiece
EP2817735A4 (en) SYSTEM AND METHOD FOR CONTEXT DETERMINATION
PL2722378T3 (pl) Sposób kruszenia lub szczelinowania odwiertu
PT2876447T (pt) Método para deteção de cancro
EP2689889A4 (en) MACHINE TOOL SYSTEM
EP2876446A4 (en) METHOD OF DETECTING CANCER
HK1208271A1 (en) Method for authenticating a timepiece
HK1208731A1 (en) Method for the detection of a multispecific binder
EP2800924A4 (en) SYSTEM AND METHOD FOR RELUBRICHING A MACHINE ELEMENT
HK1205789A1 (en) Method for selecting or identifying a subject for v1b antagonist therapy v1b
HK1205798A1 (en) Method for authenticating a timepiece
IL232355A0 (en) A method for determining calcification tendency
HK1210480A1 (en) A method for polishing albumin
HRP20190390T1 (hr) Postupak za pripremanje oksikodona
EP2862034A4 (en) METHOD FOR DETERMINING A MACHINE STATUS
EP2931743A4 (en) METHOD FOR ASSESSING IMMUNOGENICITY
HK1168501A2 (en) A positioning method
GB201211637D0 (en) A barrier apparatus
HK1206815A1 (en) Selection method for therapeutic agents
IL233868A0 (en) A method for detecting polyomavirus reactivation
GB2500319B (en) Method of testing the integrity of a barrier